AMG 145 success in Phase 1b trial for High Cholesterol

Amgen has announced positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p<0.001). the cholesterol lowering effects of amg 145 were similar among patients on high doses of statins 80 mg atorvastatin and 40 mg rosuvastatin and patients on low to moderate doses of statins. no deaths or serious adverse events aes were reported in the study. full results of the study were presented for the first time today in an oral session at the american college of cardiology scientific session in chicago . abstract 923-4>